CoChat
Sign Up
Cited by 136Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Kajinami, Kouji, Takekoshi, Noboru, Saito, Yasushi·2003·Cardiovascular Drug Reviews
DOI 10.1111/j.1527-3466.2003.tb00116.x
Open this paper in CoChat — free account

Abstract

The use of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors, statins, has been shown to reduce major cardiovascular events in both primary and secondary prevention, and statins became one of the most widely prescribed classes of drugs throughout the world. Previously, statins have been well tolerated and have shown favorable safety profiles. However, the voluntary withdrawal of cerivastatin from the market because of a disproportionate number of reports of rhabdomyolysis‐associated deaths drew attention to the pharmacokinetic profile of statins, which may possibly have been related to serious drug‐drug interactions. Pitavastatin (NK‐104, previously called itavastatin or nisvastatin, Kowa Company Ltd., Tokyo) is a novel, fully synthetic statin, which has a potent cholesterol‐lowering action. The short‐term and long‐term lipid‐modifying effects of pitavastatin have already been investigated in subjects with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, hypertriglyceridemia, and type‐2 diabetes mellitus accompanied by hyperlipidemia. Within the range of daily doses from 1 to 4 mg, the efficacy of pitavastatin as a lipid‐lowering drug seems to be similar, or potentially superior, to that of atorvastatin. According to the results of pharmacokinetic studies, pitavastatin showed favorable and promising safety profile; it was only slightly metabolized by the cytochrome P450 (CYP) system, its lactone form had no inhibitory effects on the CYP3A4‐mediated metabolism of concomitantly administered drugs; P‐glycoprotein‐mediated transport did not play a major role in its disposition, and pitavastatin did not inhibit P‐glycoprotein activity. It could be concluded that pitavastatin could provide a new and potentially better thera‐peutic choice for lipid‐modifying therapy than do the currently available statins. The ef‐ficacy and safety of higher dose treatment, as well as its long‐term effects in the pre‐vention of coronary artery disease, should be further investigated.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1527-3466.2003.tb00116.x

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 77 references

Research works printed but not linked: 6

  1. FujinoH ShimadaS YamadaI TsunenariY HiranoM KojimaJ.Interaction between fibrates and statins. In:Abstract of 13th International conference on cytochromes P450 2003(in Czech).
  2. Nakaya N, 2001, A Phase 1 clinical study of a novel HMG‐CoA reductase inhibitor, NK‐104 (pitavastatin). Results of single and 7‐day repeated oral administration studies in healthy adult male volunteers, J Clin Ther Med, 17, 741
  3. Nakaya N, 2001, Efficacy and safety of NK‐104 (pitavastatin), a novel HMG‐CoA reductase inhibitor in hypercholesterolemic volunteers, J Clin Ther Med, 17, 767
  4. Nakaya N, 2001, Pharmacokinetics of repeated Dose NK‐104 (pitavastatin), in healthy elderly and non‐elderly volunteers, J Clin Ther Med, 17, 957
  5. Ouchi Y, 2001, Efficacy and safety of NK‐104 (pitavastatin), a new HMG‐CoA reductase inhibitor in the elderly patients with hyperlipidemia, Geriatr Med, 39, 849
  6. Shimada Y, 1996, Partition coefficient and hepatic cell‐selectivity of HMG‐CoA Reductase inhibitors, Progr Med, 18, 957

Cited by

Sorted by citations

Items 101–136 of 136

Related

See all

Metadata

Authors
Kajinami, K., Takekoshi, N., & Saito, Y.
Affiliations
  • Kanazawa Medical University (JP)
  • Chiba University (JP)
Corresponding author
Kajinami, Kouji
ORCID
Saito, Yasushi
Venue
Cardiovascular Drug Reviews
Publisher
Wiley
Published
2003-09
Volume
21
Issue
3
Pages
199-215
ISSN
  • 0897-5957 (ISSN-L)
  • 1527-3466
DOI
10.1111/j.1527-3466.2003.tb00116.x
OpenAlex
W2074541010
Cited by
136
References
77
Citations by year
2026: 5 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 2
FWCI
8.31
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1010 d)
Locations
  • Cardiovascular Drug Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
pitavastatin, statins, lipid-lowering therapy, hypercholesterolemia, familial hypercholesterolemia, hypertriglyceridemia, type 2 diabetes, pharmacokinetics, drug-drug interactions, cytochrome P450, P-glycoprotein, rhabdomyolysis, atorvastatin comparison, coronary heart disease prevention
MeSH terms
Animals, Arteriosclerosis, Clinical Trials as Topic, Cytochrome P-450 Enzyme System, Drug Interactions, Humans, Hypercholesterolemia, Lipoproteins, Quinolines, Hydroxymethylglutaryl-CoA Reductase Inhibitors, ATP Binding Cassette Transporter, Subfamily B, Member 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review